Equities

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB

Actions
  • Price (SEK)1.10
  • Today's Change0.085 / 8.42%
  • Shares traded511.00
  • 1 Year change-56.89%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 08:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Modus Therapeutics Holding AB is a Sweden-based biotechnology company that through the patented polysaccharide sevuparin develops the treatment for severe diseases with large residual medical needs. The company's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-17.90m
  • Incorporated2011
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Redwood Pharma AB0.00-13.60m22.08m1.00--0.3266-----5.87-5.870.003.180.00----0.00-106.53-95.03-121.24-123.04-----------19.120.00-------8.78---5.11--
Lidds AB0.00-40.21m23.40m2.00--0.8419-----0.8316-0.83160.000.20370.00----0.00-184.54-46.33-274.93-51.61---1,934.24---3,076.68----0.00---100.00---9.08------
Cyxone AB0.00-22.99m26.13m4.00--0.6706-----0.1902-0.19020.000.18040.00-------47.81-66.19-53.03-72.35------------0.0216------45.87---12.69--
Fluicell AB3.34m-26.55m28.84m17.00--24.18--8.64-0.2201-0.22010.02820.00360.16240.68133.84196,352.90-129.20-87.55-222.48-126.0252.0772.97-795.51-650.230.5001--0.00--2.6822.18-22.90------
Elicera Therapeutics AB11.23m-16.40m34.39m2.00--1.18--3.06-0.8289-0.82890.56770.82910.2936--8.135,615,030.00-42.88-40.06-66.66-49.74-----146.02-415.41----0.00--777.23--15.64------
Lipigon Pharmaceuticals AB16.41m-12.13m37.17m----1.31--2.27-0.4662-0.46620.32010.2250.7388--14.81---54.60-314.67-75.05-426.49-----73.91-488.14----0.00----444.4467.83------
Modus Therapeutics Holding AB0.00-17.90m38.81m2.00--2.20-----1.04-1.040.000.4920.00----0.00-114.31-141.06-237.09-278.44-----------10.960.00------2.31------
Gabather AB0.00-9.44m38.90m----62.27-----0.652-0.6520.000.03310.00-------133.71-56.57-480.99-67.36-------17,298,800.00-------------10.40------
Klaria Pharma Holding AB (publ)0.00-18.39m43.13m5.00--1.05-----0.1824-0.3550.000.38620.00----0.00-19.03-37.28-31.28-51.56-------2,077.34---3.880.00---100.00--71.17------
Oncozenge AB0.00-15.90m43.46m----2.33-----1.36-1.360.001.590.00-------55.57---60.45--------------0.00------65.91------
Veg of Lund AB (publ)4.82m-19.91m44.15m7.00--1.05--9.17-0.7328-0.73280.15191.010.133713.7414.40688,000.00-55.27-129.03-82.56-209.20-384.61-781.09-413.50-923.730.1256-12.900.1405--89.5739.8756.02---12.47--
NextCell Pharma AB12.45m-39.37m44.35m----0.7943--3.56-1.15-1.150.36211.620.140614.067.20---44.45-34.92-50.09-37.0612.04-68.21-316.25-538.604.36--0.00--80.9672.85-15.21------
SoftOx Solutions AS6.99m-42.13m50.70m--------7.26-1.98-1.980.3286-0.01270.081--1.60---48.81-50.83-82.20-64.58-----602.91-646.670.1745-3.45-----1.8810.0640.85--39.43--
Alzinova AB270.00k-16.48m51.21m----0.4498--189.67-0.4149-0.41490.00672.560.0023--0.3671---14.04-10.77-14.91-11.277,360.55---6,103.69-18,447.90----0.007-------25.92--15.81--
Scandion Oncology A/S0.00-61.16m55.34m4.00--1.14-----1.52-1.520.001.190.00----0.00-63.25-45.09-76.67-52.65------------0.0158------48.89------
Pila Pharma AB1.46m-9.93m57.10m1.00--8.57--39.03-0.5304-0.53040.07670.280.1513--6.111,463,020.00-102.68-108.88-122.66-121.45-127.88-42.67-678.73-1,577.64---159.470.104---22.21--62.92------
Data as of May 17 2024. Currency figures normalised to Modus Therapeutics Holding AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.